N/A N=36 ADAM17 and Vascular Function in Diabetes
Diabetes Mellitus, Type 2
Primary: Change in Insulin-stimulated Blood Flow — -70.80; 24.79 mL/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,603 Assessing Pain, Patient Reported Outcomes and Complementary and Integrative Health
Chronic Musculoskeletal Pain
Primary: Brief Pain Inventory (BPI) Severity Scale — 5.9; 6.0; 6.3; 5.3 units on a scale — p=0.160
N/A N=20 The Use of the Functional Movement Screen™ in Preventing Injuries in Amateur Rugby Players
Prevention · Risk · Injuries
Primary: The FMS™ Score — 13.5 FMS Score
Phase 1 N=19 Itacitinib in Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Primary: To Assess the Safety and Tolerability of Itacitinib in Patients With HCC: Adverse Events — 14 Participants
Phase 1 N=58 First in Human Study of M6223
Metastatic Solid Tumors
Primary: Part 1A and 1B: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs) Assessed Using National Cancer Institute (NCI) Common Toxicity Criteria for…
Phase 3 N=68 Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo
Surgery
Primary: Society of Thoracic Surgery (STS) Quality Benchmark of Early Extubation Criteria — 31; 31 Participants
Phase 2 N=345 Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria
Malaria
Primary: Primary Safety Endpoint - The Number of Adverse Events Occurring After Investigational Product (IP) Administration — 6; 5; 8; 3 participants
N/A N=14 Accuracy of ScanWatch Pulse Oximeter With Profound Hypoxia
Oximetry
Primary: RMSE Compared to CO-oximetry — 2.97; 3.00 RMSE (%)
Phase 1 N=24 An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Primary Biliary Cholangitis · Compensated Cirrhosis · Hepatic Impairment
Primary: Part A: Pharmacokinetic (PK) Parameter: Cmax of Seladelpar and Its Metabolites (M1, M2, and M3) — 182.0; 367.7; 359.2; 388.5 nanograms per milliliter (ng/mL)
N/A N=11 Comparative Ultrasound Analysis of Two Hyaluronic Acid Dermal Fillers
Volume Deficiency of the Midface
Primary: Assess and Compare Tissue Aggregation and Visualization of Hyaluronic Acid Fillers by Investigator Using Ultrasound — 10; 1; 7; 9 Participants
N/A N=6,544 Online Grammatical Reasoning Training for Older Adults
Healthy Aging
Primary: Change in Executive Function From Baseline — 5435.9; 9671.19 score on a scale
Phase 2 N=64 Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Phase 1 N=36 Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults
Enterovirus Infection
Primary: Number of Participants Experiencing Solicited Adverse Events (AEs) Through 48 Hours Post-infusion — 7; 4; 3; 3 Participants
Phase 2 N=120 Assessing Gingivitis of 3 Different Dentifrices Compared to a Negative Control.
Gingivitis
Primary: Number Bleeding Sites — 31.52; 25.90; 21.65; 19.13 number of bleeding sites
Phase 3 N=16 Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)
Hypereosinophilic Syndrome
Primary: Number of Participants Who Experienced HES Flares Over the 52-Week Study Treatment Period — 10; 4; 1; 1 Participants